Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Receivables (2017 - 2025)

Heron Therapeutics (HRTX) has disclosed Change in Receivables for 11 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables fell 27.88% year-over-year to $8.5 million, compared with a TTM value of $10.7 million through Dec 2025, down 42.88%, and an annual FY2025 reading of $10.7 million, down 42.88% over the prior year.
  • Change in Receivables was $8.5 million for Q4 2025 at Heron Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $25.2 million in Q2 2023 and bottomed at -$12.9 million in Q3 2023.
  • Average Change in Receivables over 5 years is $2.4 million, with a median of $1.2 million recorded in 2025.
  • Peak annual rise in Change in Receivables hit 3255.62% in 2023, while the deepest fall reached 784.24% in 2023.
  • Year by year, Change in Receivables stood at -$7.6 million in 2021, then skyrocketed by 229.97% to $9.9 million in 2022, then crashed by 137.1% to -$3.7 million in 2023, then soared by 423.73% to $11.8 million in 2024, then fell by 27.88% to $8.5 million in 2025.
  • Business Quant data shows Change in Receivables for HRTX at $8.5 million in Q4 2025, $1.1 million in Q3 2025, and $1.2 million in Q2 2025.